Search
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Ioversol
go.drugbank.com/drugs/DB09134ApprovedInvestigational[L41780] Ioversol is a highly hydrophilic agent considered to be generally safe[L41790]; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol … [L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left
Synonyms: N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamideCategories: Compounds used in a research, industrial, or household settingDiflunisal
go.drugbank.com/drugs/DB00861ApprovedDiflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
Products: Nu-diflunisal Tab 500mg, Nu-diflunisal Tab 250mgAntithrombin III human
go.drugbank.com/drugs/DB11598ApprovedInvestigationalA plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Products: KYBERNIN P 500 IU IV ENJEKSİYONLUK İNFÜZYONLUK LİYOFİLİZE TOZ VE ÇÖZÜCÜ, ANBİNEX 500 IU/10 ML IV İNFÜZYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON VE ÇÖZÜCÜSÜSpirapril
go.drugbank.com/drugs/DB01348ApprovedInvestigationalACE inhibitors are used primarily in treatment of hypertension and congestive heart failure. … Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration.
Categories: Agents Acting on the Renin-Angiotensin SystemNateglinide
go.drugbank.com/drugs/DB00731ApprovedDue to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. … Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight.
Categories: Drugs Used in DiabetesBimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]
MVC-COV1901
go.drugbank.com/drugs/DB15854InvestigationalThe vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).
Fomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnThe drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development … It is an antiviral agent that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS.
Categories: Compounds used in a research, industrial, or household settingOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell